Press "Enter" to skip to content

Pfizer And Eli Lilly Are Trying To Develop A Promising Opioid Alternative

Two pharmaceutical companies—Pfizer Inc. and Eli Lilly &Co.—have developed a pain relieving medication that showed effective results against osteoarthritis, which is the most common chronic joint condition usually occurs in aged individuals. Centers for Disease Control and Prevention reported that at present more than 30 Million U.S. citizens are affected by osteoarthritis. The companies announced about the medication late on Tuesday.

Various investors will thoroughly examine the effectiveness of medication by analyzing the clinical trials’ results. A few years back, the clinical trials were held for the development of the drug ‘tanezumab”, the same drug which Pfizer and Eli Lilly have been trying to develop. The results of phase 3 trial revealed that the osteoarthritis condition of the group of patients taking this class of drugs got worse as compared to the condition of the group of patients taking a placebo. These results hold the clinical development of the drug for some years.

Ken Verburg (clinical program development lead at Pfizer) said that both the companies are dedicated to the same path working over the same drug. The data from the previous clinical trials was not much promising; as the patients affected by the drug are very few, and the symptoms caused by the drug and placebo are not clearly linked. The companies were waiting to get some sort of balanced results from both the groups of patients.

According to both the companies, in another clinical trial, in which patients were given painkiller medicines like ibuprofen and opioids did not get effective results. However, the patients who were given tanezumab under different conditions shown considerable improvements as compared to patients given a placebo.

Teva Pharmaceutical Industries and Regeneron Pharmaceuticals Inc. are working over the development of similar kind of drug known as fasinumab, which also reduces pain by targeting over the nerve growth factor.